An interventional study of Parenteral nutrition and Enteral nutrition in Acute Respiratory Failure and Shock, sponsored by Centre Hospitalier Departemental Vendee. Terminated at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-26.
Sponsored by Centre Hospitalier Departemental Vendee · Not applicable, Interventional, and Prevention
Among 107 studies in Shock with a site in France — 24 open to participants now, 27 under way, 1 of them phase 3. Shock · France.
Among the 107 studies in Shock with a site in France, this one is the 23rd largest by enrollment of the 46 interventional ones that give a count, is one of 7 that started in 2015, is one of 32 with no phase, and was the 37th registered.
487 studies on the registry are indexed under Shock; 107 are open to participants now.
Browse Shock studies →24 of the 107 studies in Shock with a site in France are open now. Recruiting first, the newest first:
CHU de Reims · Sites in France
Ages 18+
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Bicetre Hospital · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 0 days–3 mo
University Hospital, Bordeaux · Sites in France
Ages 0 days–15 yrs
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 68 Shock studies recruiting now, 52 (76%) set no upper age limit and 11 (16%) stop at 75 or younger; 9 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 139 is above the median of 100 across 229 interventional studies indexed under Shock.
Median enrollment 139 across the 46 interventional studies, 100 across the 61 observational. Of the 66 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 107 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Departemental Vendee is the lead sponsor of 83 studies on the registry; 12 are open to participants now.
Centre Hospitalier Departemental Vendee has 3 studies filed under Shock — fewer than ten, so there is no comparison to draw.
11 of the studies in Shock with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07724262Bicetre HospitalEvaluation of the Argos System to Estimate Cardiac Output | 2026-12-31 |
| NCT05655065University Hospital, AngersEffects of Increasing Mean Arterial Pressure on Renal Function in Patients With Shock and With Elevated Central Venous Pressure | 2026-12-31 |
| NCT07255469University Hospital, BordeauxMetabolic Fluid Responsiveness in Children | 2027-03-21 |
| NCT07203833Centre Hospitalier Universitaire, AmiensDiagnostic and Prognostic Evaluation of Vasorin During Septic Shock | 2027-04 |
| NCT06839404Bicetre HospitalPharmacodynamic Analysis of the HaemOdynamic Effects of a Standard Fluid BolUS | 2027-06-30 |
Among the 107 studies in Shock with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the impact of enteral nutrition on microaspiration of gastric content and pharyngeal secretions
A common obstacle to enteral nutrition is gastrointestinal intolerance, with regurgitations potentially responsible for gastric-content aspiration. Several studies involving technetium 99m (99mTc) labeling of gastric contents have established that gastric-fluid microaspiration is common in critically ill patients receiving both endotracheal ventilation and enteral nutrition. However, to our knowledge, no studies have specifically addressed the role for enteral nutrition in the occurrence of microaspiration. The objective of this ancillary study is to compare the frequency of gastric-content microaspiration in patients given enteral versus parenteral nutrition during the NUTRIREA2 trial. The new knowledge of risk factors for microaspiration provided by this study may help to improve strategies for preventing microaspiration and ventilator-associated pneumonia (VAP).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level \< 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
Other: Parenteral nutrition
Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
Other: Enteral nutrition
Also known as: Intravenous nutrition, Intravenous feeding
Also known as: Enteral feeding
proportion of patients with abundant microaspiration (defined as a pepsin level >200 ng/mL in at least 30% of tracheal aspirates)
Every tracheal aspirate will be collected during 48hours following randomisation
Time frame: 48Hours following randomisation
Salivary amylase levels in tracheal aspirates.
Every tracheal aspirate will be collected during 48hours following randomisation. Salivary amylase will be analysed.
Time frame: 48Hours following randomisation
Ran from Jan 2015 to primary completion in Jul 2015, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Departemental Vendee